136 related articles for article (PubMed ID: 21884245)
1. Interleukin-28B genetic variations and response to interferon-based therapy: Asian perspectives.
Liu CH; Kao JH
J Gastroenterol Hepatol; 2011 Sep; 26(9):1348-53. PubMed ID: 21884245
[No Abstract] [Full Text] [Related]
2. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients.
Sinn DH; Kim YJ; Lee ST; Gwak GY; Choi MS; Lee JH; Koh KC; Yoo BC; Paik SW
J Gastroenterol Hepatol; 2011 Sep; 26(9):1374-9. PubMed ID: 21501223
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-28B genotypes determine response to pegylated-interferon plus ribavirin therapy in patients with hepatitis C virus infection.
Osaki R; Nishimura T; Shioya M; Takeuchi T; Okumura Y; Nakahara T; Bamba S; Nakajo S; Fujiyama Y; Andoh A
Mol Med Rep; 2012 Feb; 5(2):525-8. PubMed ID: 22052088
[TBL] [Abstract][Full Text] [Related]
4. Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin.
Ridruejo E; Solano A; Marciano S; Galdame O; Adrover R; Cocozzella D; Delettieres D; Martínez A; Gadano A; Mandó OG; Silva MO
Ann Hepatol; 2011; 10(4):452-7. PubMed ID: 21911885
[TBL] [Abstract][Full Text] [Related]
5. Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.
Liu CH; Liang CC; Liu CJ; Tseng TC; Lin CL; Yang SS; Su TH; Hsu SJ; Lin JW; Chen JH; Chen PJ; Chen DS; Kao JH
Antivir Ther; 2012; 17(3):477-84. PubMed ID: 22301466
[TBL] [Abstract][Full Text] [Related]
6. Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis.
Cariani E; Roli L; Missale G; Villa E; Ferrari C; Trenti T
Pharmacogenomics J; 2016 Feb; 16(1):18-29. PubMed ID: 25918016
[TBL] [Abstract][Full Text] [Related]
7. Role of interleukin 28B-related gene polymorphisms in chronic hepatitis C and the response to antiviral therapy in Koreans.
Jung YK; Kim JH; Ahn SM; Yang JW; Park SJ; Kim JW; Yeon JE; Kwon OS; Kim YS; Choi DJ; Kim JH; Byun KS
J Clin Gastroenterol; 2013 Aug; 47(7):644-50. PubMed ID: 23442843
[TBL] [Abstract][Full Text] [Related]
8. IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.
Rosso C; Abate ML; Ciancio A; Strona S; Caviglia GP; Olivero A; Touscoz GA; Rizzetto M; Pellicano R; Smedile A
World J Gastroenterol; 2014 Sep; 20(36):13146-52. PubMed ID: 25278709
[TBL] [Abstract][Full Text] [Related]
9. No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients.
Heo NY; Lim YS; Lee W; Oh M; An J; Lee D; Shim JH; Kim KM; Lee HC; Lee YS; Suh DJ
Clin Mol Hepatol; 2014 Jun; 20(2):177-84. PubMed ID: 25032184
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-28B polymorphisms on the SVR in the treatment of naïve chronic hepatitis C with pegylated interferon-α plus ribavirin: a meta-analysis.
Shi KQ; Liu WY; Lin XF; Fan YC; Chen YP; Zheng MH
Gene; 2012 Oct; 507(1):27-35. PubMed ID: 22842190
[TBL] [Abstract][Full Text] [Related]
11. Interferon-λ-related genes and therapeutic response in Chinese hepatitis C patients.
Zhang YY; Chen HB; Xu Y; Huang P; Wang J; Zhang Y; Yu RB; Su J
World J Gastroenterol; 2015 Apr; 21(13):4006-13. PubMed ID: 25852288
[TBL] [Abstract][Full Text] [Related]
12. [IL-28B polymorphism and hepatitis C: impact on viral clearance--prolonged, spontaneous and after treatment with antiviral drugs].
Halfon P; Cacoub P
Rev Med Interne; 2011 May; 32(5):271-4. PubMed ID: 21126807
[No Abstract] [Full Text] [Related]
13. A single nucleotide polymorphism in IL28B affects viral evolution of hepatitis C quasispecies after pegylated interferon and ribavirin therapy.
Yuan H; Adams-Huet B; Petersen T; Attar N; Lee WM; Jain MK
J Med Virol; 2012 Dec; 84(12):1913-9. PubMed ID: 23080496
[TBL] [Abstract][Full Text] [Related]
14. [PROGNOSTIC VALUE OF THE COMBINATION OF BLOOD GROUP SPECIFICITY AND INTERLEUKIN 28B GENE POLYMORPHISM FOR ESTIMATION OF EFFICIENCY OF THERAPY WITH THE USE OF PEGYLATED INTERFERON α-2 AND RIBAVARIN IN PATIENTS WITH CHRONIC GENOTYPE 1 HEPATITIS C].
Ogurtsov PP; Kukhareva EI
Klin Med (Mosk); 2016; 94(3):224-30. PubMed ID: 27522730
[TBL] [Abstract][Full Text] [Related]
15. Optimum ribavirin exposure overcomes racial disparity in efficacy of peginterferon and ribavirin treatment for hepatitis C genotype 1.
Jin R; Cai L; Tan M; McHutchison JG; Dowling TC; Howell CD
Am J Gastroenterol; 2012 Nov; 107(11):1675-83. PubMed ID: 23090351
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C.
Jeong SH; Jung YK; Yang JW; Park SJ; Kim JW; Kwon OS; Kim YS; Choi DJ; Kim JH
Clin Mol Hepatol; 2012 Dec; 18(4):360-7. PubMed ID: 23323251
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin.
Hayashi K; Katano Y; Kuzuya T; Tachi Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Ishikawa T; Nakano I; Urano F; Yoshioka K; Toyoda H; Kumada T; Goto H
J Med Virol; 2012 Mar; 84(3):438-44. PubMed ID: 22246829
[TBL] [Abstract][Full Text] [Related]
18. IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C.
Cieśla A; Bociąga-Jasik M; Sobczyk-Krupiarz I; Głowacki MK; Owczarek D; Cibor D; Sanak M; Mach T
World J Gastroenterol; 2012 Sep; 18(35):4892-7. PubMed ID: 23002361
[TBL] [Abstract][Full Text] [Related]
19. Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4.
Domagalski K; Pawłowska M; Tretyn A; Halota W; Pilarczyk M; Smukalska E; Linkowska K; Grzybowski T
Eur J Clin Microbiol Infect Dis; 2013 Jun; 32(6):745-54. PubMed ID: 23314745
[TBL] [Abstract][Full Text] [Related]
20. IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis.
Rangnekar AS; Fontana RJ
J Viral Hepat; 2013 Jun; 20(6):377-84. PubMed ID: 23647954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
